home
RSS
January 20th, 2012
06:44 PM ET

MS drug Gilenya under safety review

Health agencies on both sides of the Atlantic are investigating reports of 11 deaths in multiple sclerosis patients taking Gilenya, the first multiple sclerosis drug approved in pill form. 

The U.S. Food and Drug Administration confirmed Friday that it is studying data on Gilenya (fingolimod).  "We will notify the public once our review is complete to communicate any recommendations or possible label changes," the FDA said in a statement to CNN.

The investigation comes on the heels of the European Medicines Agency  announcing, that they are reviewing the drug, after reports of several deaths from heart problems in patients.

Gilenya was approved for the treatment of relapsing-remitting multiple sclerosis in 2010.  The FDA recommends that before patients start on the drug, they are made aware of potential heart-rate problems.  The agency further recommends that patients only take Gilenya at their physician's office , where they are monitored for six hours after they take the first dose.

The Swiss pharmaceutical company Novartis says last November it was "notified of the first reported case of a patient death that occurred within 24 hours after receiving the first dose of Gilenya."  In a statement to CNN, the company says the cause of death remains unknown.  Ten more patients taking the medication have died, due to sudden death, heart attack or disruption of the heart rhythm, according to Novartis.  "As noted by EMA, it is currently not clear whether these deaths were caused by Gilenya or not," 

The company points out that in clinical trials, there was not an imbalance in deaths of patients on the drug and incidents in the general population.

The National Multiple Sclerosis Society notes that it unclear what role Gilenya may have played in these deaths and is waiting for the results of the investigation.  Dr. Timothy Coetzee, chief research officer for the National MS Society, says "understanding the benefits and risks of therapies is vitally important to everyone in the MS community."

In addition, the organization stresses the importance of the EMA's recommendation for heightened monitoring procedures after the first dose is administered.

The MS Society recommends patients currently taking this drug consult their doctor or contact the Novartis patient support line at 888-NOW-NOVA (888-669-6682) for more information.


soundoff (56 Responses)
  1. tadalafil 30 mg

    tadalafil generic https://elitadalafill.com/ tadalafil pills

    April 6, 2021 at 19:02 | Report abuse | Reply
  2. vardenafil prices india

    vardenafil grapefruit interaction https://vegavardenafil.com/ generic levitra vardenafil 20mg

    April 6, 2021 at 23:39 | Report abuse | Reply
  3. sildenafil tablets india

    sildenafil cheap no prescription https://eunicesildenafilcitrate.com/ sildenafil uk cheapest

    April 7, 2021 at 12:26 | Report abuse | Reply
  4. Private Proxy Http

    Nearly all of what you state happens to be supprisingly appropriate and that makes me ponder the reason why I hadn't looked at this in this light previously. This particular article truly did turn the light on for me personally as far as this subject goes. Nevertheless at this time there is actually one point I am not really too comfortable with and whilst I try to reconcile that with the actual main theme of the point, let me observe exactly what all the rest of your subscribers have to point out.Well done.

    https://dreamproxies.com/buy-proxies/200-private-proxies/

    April 8, 2021 at 07:29 | Report abuse | Reply
  5. Jefferson

    My partner and I stumbled over here coming from a different website and thought I might check things out. I like what I see so now i'm following you. Look forward to checking out your web page again.

    https://t.co/QvH2Kejsag?amp=1

    April 12, 2021 at 09:15 | Report abuse | Reply
  6. zithromax 100 mg

    zithromax azithromycine https://zithromaxes.com/ sithro

    April 13, 2021 at 01:25 | Report abuse | Reply
1 2

Leave a Reply to ClarkTauts


 

CNN welcomes a lively and courteous discussion as long as you follow the Rules of Conduct set forth in our Terms of Service. Comments are not pre-screened before they post. You agree that anything you post may be used, along with your name and profile picture, in accordance with our Privacy Policy and the license you have granted pursuant to our Terms of Service.

Advertisement
About this blog

Get a behind-the-scenes look at the latest stories from CNN Chief Medical Correspondent, Dr. Sanjay Gupta, Senior Medical Correspondent Elizabeth Cohen and the CNN Medical Unit producers. They'll share news and views on health and medical trends - info that will help you take better care of yourself and the people you love.